Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Boone Health is closing its bariatric clinic in Columbia because of lagging demand. "We're working to expand the high-demand ...

A small number of patients using GLP-1 weight loss medications have experienced vision loss, although researchers have not ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Similarly, Zepbound is Mounjaro's weight-loss counterpart ... said many of his patients report life-changing weight loss while on GLP-1 medications. "I have some veterans who have lost 70 to ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...